Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Rectal Neoplasms 1Precancerous Conditions 1Ovarian Neoplasms 1Lymphatic Metastasis 1Liver Neoplasms 1Keratosis, Actinic 1Gallbladder Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Colorectal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Carcinoma, Basal Cell 1Carcinoma 1Biliary Tract Neoplasms 1

Interventions

Paclitaxel 95Carboplatin 76pembrolizumab 72Cisplatin 28Bevacizumab 27Surveys and Questionnaires 23Radiotherapy 22Letrozole 22Doxorubicin 21Megestrol Acetate 20olaparib 19lenvatinib 19Taxes 17Specimen Handling 17Docetaxel 17Nivolumab 16Magnetic Resonance Spectroscopy 16dostarlimab 15Metformin 15Observation 13Gemcitabine 13Blood Specimen Collection 13Biopsy 13durvalumab 12Medroxyprogesterone Acetate 12Trastuzumab 11Indocyanine Green 11Fulvestrant 11temsirolimus 10abemaciclib 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × Methylation × Clear all
NCT01850654 2018-06-28

OCCPI

Ohio State University Comprehensive Cancer Center

Phase NA Completed
3,470 enrolled
GastrointestinalGynecologic

Colonic Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡